Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126119) titled 'Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC' on Aug. 9.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Tianjin Medical University Second Hospital

Condition: Upper Tract Urothelial Carcinoma Neoadjuvant Therapy PD-1 Inhibitor Nab-paclitaxel

Intervention: Drug: Nab-Paclitaxel Drug: Tislelizumab

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: July 5, 2025

Target Sample Size: 35

Countries of Recruitment: China

To know more, visit ...